G. Corey

发表

Treatment Protocols for Bacterial Endocarditis and Infection of Electrophysiologic Cardiac Devices

G. Corey, 2005 .

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

M. Niederman, M. Kollef, A. Shorr, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA.

Ronald N. Jones, M. Stryjewski, G. Corey, 2015, Diagnostic microbiology and infectious disease.

Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure

A. Torres, E. Rubinstein, S. Barriere, 2014, The Journal of antimicrobial chemotherapy.

Late ventilator-associated pneumonia: analysis of baseline characteristics and clinical outcomes in the ATTAIN studies

E. Rubinstein, T. Lalani, S. Barriere, 2010, Critical Care.

Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies

G. Corey, M. Stryjewski, E. Nannini, 2012, Expert review of anti-infective therapy.

TD-1792 versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections

P. Potgieter, G. Corey, S. Barriere, 2012, Antimicrobial Agents and Chemotherapy.

New treatments for methicillin-resistant Staphylococcus aureus

G. Corey, M. Stryjewski, G. Corey, 2009, Current opinion in critical care.

Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections

A. Shorr, Anita F. Das, G. Corey, 2014, Antimicrobial Agents and Chemotherapy.

Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.

M. Stryjewski, E. Nannini, G. Corey, 2012 .

Single-dose oritavancin in the treatment of acute bacterial skin infections.

W. O'Riordan, G. Corey, G. Moeck, 2014, The New England journal of medicine.

Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance

G. Corey, S. Barriere, M. Stryjewski, 2015, Antimicrobial Agents and Chemotherapy.

Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.

B. Kreiswirth, W. O'Riordan, D. Sahm, 2016, International journal of antimicrobial agents.

Short-course therapy for bloodstream infections in immunocompetent adults.

M. Stryjewski, G. Corey, Richard J. Everts, 2009, International Journal of Antimicrobial Agents.

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.

V. Fowler, S. Wilson, W. O'Riordan, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies

P. Altmeyer, G. Rahav, D. Zeltser, 2018, Antimicrobial Agents and Chemotherapy.

Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.

W. O'Riordan, G. Corey, G. Moeck, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials

G. Corey, S. Armstrong, T. Lodise, 2017, Open forum infectious diseases.

M. Stryjewski, Peter Kirkpatrick, G. Corey, 2009, Nature Reviews Drug Discovery.

Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.

A. Shorr, G. Corey, T. Hardin, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia

E. Rubinstein, G. Corey, Z. Kanafani, 2011, Expert opinion on pharmacotherapy.

Skin and soft tissue infections

G. Archer, V. Fowler, K. Jefferson, 2009 .

Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.

M. Wilcox, G. Corey, M. Dryden, 2019, International Journal of Antimicrobial Agents.